No abstract

No abstract

No abstract

Introduction: A significant proportion of patients with embolic stroke of unknown source (ESUS) are subsequently diagnosed with atrial fibrillation (AF). Left atrial myopathy characterized by mechanical left atrial dysfunction has been associated with development of AF. Hypothesis: Decreased left atrial emptying fraction (LAEF) is independently associated with AF in patients with ESUS. Methods: Patients admitted at a tertiary care medical center for ESUS treated with implantable loop recorders from 2015-2022 were included. Patients were excluded for lack of an interpretable transthoracic echocardiogram during sinus rhythm and electrocardiogram with 6 months of ESUS. Patients were also excluded for lack of clinical follow-up. Co-variates (table) were ascertained from chart review. LAEF was calculated by Simpson’s method of discs. Results: 153 patients were included. The mean(standard deviation) LAEF of patients who developed and did not develop AF within 1 year post ESUS was 48.0%(17.0%) and 57.6%(13.1%), respectively (P<0.001). The odds of diagnosing atrial fibrillation within 1 year post ESUS were 7.18-fold greater in patients with LAEF<40%. Conclusions: LAEF is independently associated with increased odds of AF within 1 year post ESUS. Future research is needed to validate these findings.

Compound 9 was specifically developed as an agonist for PPAR beta/delta. Binding studies showed it also bound PPAR gamma. Because of the recent identification of PPAR beta/delta involvement in a number of cancers, we tested whether compound 9 would synergize with known chemotherapeutic agents to increase apoptosis in a human cancer cell line that expresses the PPAR beta/delta receptor. These studies revealed that compound 9 was capable of inducing apoptosis on its own, and did not synergize with doxorubicin in inducing apoptosis. We have undertaken a series of studies to determine if the apoptosis that compound 9 induces is being mediated through any of the PPAR receptors. We have also examined compound 9 ability to signal through the PPAR receptors in a variety of cell lines.This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.